Alpha DNA Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpha DNA Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-439	Closed	-$313K	–	144
2024 Q4	$313K	Sell	439 -191	-30%	-$160K	0.12%	184
2024 Q3	$662K	Buy	630 +281	+81%	+$313K	0.25%	93
2024 Q2	$367K	Sell	349 -257	-42%	-$249K	0.14%	178
2024 Q1	$583K	Sell	606 -735	-55%	-$699K	0.22%	109
2023 Q4	$1.18M	Buy	1,341 +712	+113%	+$586K	0.46%	40
2023 Q3	$518K	Buy	+629	New	+$494K	0.21%	134
2021 Q2	–	Sell	-34	Closed	-$16K	–	525
2021 Q1	$16K	Buy	34 +3	+10%	+$1.46K	0.02%	265
2020 Q4	$14K	Buy	+31	New	+$16.7K	0.01%	281

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpha DNA Investment Management's REGN Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 439 shares — an estimated $313K sold.

Alpha DNA Investment Management first reported a position in REGN in Q4 2020 and held it in 8 quarters. The position peaked at $1.18M in Q4 2023. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Alpha DNA Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 439 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $313K.
Alpha DNA Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Alpha DNA Investment Management's Regeneron Pharmaceuticals position peaked at $1.18M in Q4 2023.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.